Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Adults (1)
- BMP2 (1)
- C-reactive protein (CRP) and Calprotectin (CAL) (1)
- Crohn’s disease (1)
- Dietry Therapy (1)
-
- Diversity (1)
- Dopaminergic neurons (1)
- Dysbiosis (1)
- GDF5 (1)
- IBD drugs (1)
- Inflammatory biomarkers (1)
- Inflammatory bowel disease (1)
- Ireland (1)
- Limonene (1)
- Lived Experience (1)
- Microbiome (1)
- Microbiota (1)
- Neuro-inflammation. (1)
- Neurodegeneration (1)
- Neurodegenerative (1)
- Neurotrophic factors (1)
- Oxidative stress (1)
- PKU (1)
- Parkinson's Disease (1)
- Parkinson’s disease (1)
- Phenylketonuria (1)
- Phytochemical (1)
- RET (1)
- Rotenone (1)
- Therapeutics (1)
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Deciphering The Salivary Microbiome In Crohn’S Disease Patients With Different Factors Contributing To Dysbiosis, Hala Elzayat
Deciphering The Salivary Microbiome In Crohn’S Disease Patients With Different Factors Contributing To Dysbiosis, Hala Elzayat
Theses
Crohn’s Disease (CD) is a chronic Inflammatory Bowel Disease (IBD), common in the UAE. Microbiota is necessary to maintain a balanced gut environment which is essential for good health. Dysbiosis can predispose to many diseases including CD. The oral cavity has the second largest and most diverse microbiota after the gut harboring over 700 species of bacteria. This study aims to investigate the alterations in the salivary microbiome in patients with CD compared to Healthy controls (HC). It also aims to compare CD patients for salivary microbiome complexity and diversity according to different factors that can contribute to dysbiosis, including …
Role Of Limonene In An Experimental Model Of Rotenone Induced Parkinson’S Disease, Lujain Mohamad Bader Eddin
Role Of Limonene In An Experimental Model Of Rotenone Induced Parkinson’S Disease, Lujain Mohamad Bader Eddin
Theses
Parkinson's disease (PD) is one of the prevalent neurodegenerative diseases in elderly population. The symptoms of PD often begin with motor and cognitive impairment that are attributed to the dopaminergic neurons degeneration. Rotenone (ROT) is a naturally derived pesticide that is used in agriculture to control pests. It is a neurotoxin well-established for use in resembling PD symptoms in research. Limonene (LMN) is a plant derived monoterpene extracted from citrus peel with a wide range of therapeutic effects. Due to the shortage in available therapeutic agents that can cure or halt the progressive degeneration of PD, the main aim of …
Defining The Potential Of Gene Therapy With Bone Morphogenetic Proteins As A Novel Therapeutic Approach In Parkinson’S Disease, Susan Rebecca Goulding
Defining The Potential Of Gene Therapy With Bone Morphogenetic Proteins As A Novel Therapeutic Approach In Parkinson’S Disease, Susan Rebecca Goulding
Theses
Parkinson’s disease is a neurodegenerative disorder, characterised by the progressive degeneration of midbrain dopaminergic neurons, and the intracellular aggregation of the α-synuclein protein in neurons throughout the nervous system. These changes result in the characteristic motor impairments in Parkinson’s disease. Current treatments are solely symptomatic and therefore there is an unmet clinical need to develop new disease-modifying therapies that can alter disease progression. For over 25 years, one proposed experimental therapy has focused on the delivery of proteins called neurotrophic factors to the brain to prevent dopaminergic neuron degeneration. However, to date, clinical trials using the most well-known neurotrophic factors …
Living With Pku: The Lived Experience Of Irish Adults With Early Diagnosed Phenylketonuria On Long Term Dietary Therapy, Mary-Ellen O'Shea
Living With Pku: The Lived Experience Of Irish Adults With Early Diagnosed Phenylketonuria On Long Term Dietary Therapy, Mary-Ellen O'Shea
Theses
Phenylketonuria (PKU) is a rare genetic condition affecting the body’s ability to metabolise the amino acid phenylalanine (PHE). A build-up of PHE in the blood and brain can result in irreversible intellectual disability and developmental delays. Ireland has one of the highest prevalence rates of PKU in Europe and some of the earliest treated patients with PKU in the world. However, little is known about their lived experience with PKU. Furthermore, cost-benefit analysis of treatments for rare diseases in Ireland is principally based on quantitative data. More qualitative data is needed to highlight the quality of life experienced by people …